Can-Fite BioPharma (NYSE:CANF) Coverage Initiated at StockNews.com

Research analysts at StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a report issued on Wednesday. The firm set a “hold” rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Can-Fite BioPharma in a report on Thursday, May 9th.

Can-Fite BioPharma Stock Performance

Shares of CANF stock opened at $2.40 on Wednesday. The business’s 50 day moving average price is $2.44 and its 200-day moving average price is $2.23. The firm has a market cap of $8.50 million, a P/E ratio of -1.34 and a beta of 1.45. Can-Fite BioPharma has a fifty-two week low of $1.81 and a fifty-two week high of $4.48.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently bought a new stake in Can-Fite BioPharma stock. Schechter Investment Advisors LLC purchased a new position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 20,077 shares of the company’s stock, valued at approximately $44,000. Schechter Investment Advisors LLC owned 0.57% of Can-Fite BioPharma as of its most recent SEC filing. 21.00% of the stock is currently owned by institutional investors.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.